Drug-resistant "superbugs" are now killing more than 50,000 Americans and infecting nearly 10 million people annually, according to a new comprehensive assessment released by the Centers for Disease Control and Prevention. This marks the first time in seven years that the federal health agency has issued such a detailed evaluation of drug-resistant bacteria and fungi. The report identifies 19 pathogens that currently pose a direct threat to human health in the United States, alongside another six germs being monitored as potential future risks.
These resistant pathogens have evolved to withstand medications designed to eliminate them, including antibiotics, antifungals, antiparasitics, and antivirals. Experts attribute this crisis to the misuse and overuse of these treatments, compounded by environmental factors such as rising global temperatures that appear to aid the proliferation of superbugs. When infections no longer respond to standard therapies, patients face prolonged recovery times and more severe illnesses. The risks are particularly acute for individuals with compromised immune systems, underlying health conditions, or those utilizing medical devices like catheters and ventilators.
Healthcare settings remain a critical area of concern. The CDC estimates that healthcare-associated infections caused by these resistant germs were responsible for more than 42,000 deaths and nearly $12 billion in healthcare costs in 2023. Wendy Armstrong, president of the Infectious Diseases Society of America, noted that superbugs prolong hospital stays, drive up costs, and make it increasingly difficult for doctors to provide safe care.
The report categorizes drug-resistant pathogens into three threat levels: urgent, serious, or concerning, with an additional watch list for germs under investigation. Four specific pathogens are classified as "urgent," the highest threat level. These include Candida auris, a fungus that spreads easily in hospitals and has seen clinical cases increase by more than 50 percent between 2022 and 2023. Another urgent threat is Neisseria gonorrhoeae, which causes gonorrhea and has developed resistance to nearly every available antibiotic. The remaining two urgent germs are Acinetobacter and Enterobacterales, bacteria common in healthcare settings that are now resistant to powerful carbapenem antibiotics, leaving patients with limited treatment options.
Despite the troubling data, the report highlights areas of progress. The CDC has downgraded Clostridioides difficile, or "C. diff," noting a decline in cases from 455,560 in 2018 to 412,504 in 2023, likely due to improved diagnosis and infection prevention efforts. Erica Schwartz, director of the CDC, stated that the findings demonstrate both the progress made and the significant work that remains. The agency plans to release updates every two years, though it cautioned against direct numerical comparisons with the 2019 report due to changes in data sources and methods.
Globally, the threat of superbugs continues to grow, with research suggesting antibiotic-resistant infections could result in more than 39 million deaths by 2050. While new antibiotics have been developed recently, experts warn that current efforts may not keep pace with evolving bacteria. Yvan Hutin, formerly the director of antimicrobial resistance at the World Health Organization, emphasized the need for a reliable pipeline of innovative and affordable antibacterial agents to address this escalating public health crisis.
Sources: Smithsonian Magazine.